



## Revised table in 2012 Annual Report

**Melbourne – October 8, 2012: Prana Biotechnology Limited (NASDAQ:PRAN; ASX:PBT)** today announced that it has identified the below correction to a table lodged in the Company's Annual Report on 28 September 2012. The table appears on page 45 on the notes to the financial statements in the annual report. The correction related to 2012 "Short-term employee benefits" and "Post-employment benefits". The revised table is listed below:

### c. Key Management Personnel Compensation

The aggregate compensation made to Key Management Personnel of the Company is set out below:

	2012	2011
	\$	\$
Short-term employee benefits	1,034,718	1,140,420
Post-employment benefits	64,253	90,527
Long-term benefits	-	-
Termination benefits	-	-
Share-based payments	30,806	-
	1,129,777	1,230,947

Additional disclosures required as per AASB 124 can be found in sections A to E of the Remuneration Report.

Finalisation of printing of the annual report is now underway and Prana looks forward to the report being dispatched to all shareholders who have nominated to receive a hard copy of the report in the near future. The revised report will also be released on the ASX at that same time.

### About Prana Biotechnology Limited

Prana Biotechnology was established to commercialize research into age-related neurodegenerative disorders. The Company was incorporated in 1997 and listed on the Australian Securities Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

For further information please visit the Company's web site at [www.pranabio.com](http://www.pranabio.com).